Jazz Pharmaceuticals (FRA:J7Z) Current Deferred Revenue: €0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J7Z Jazz Pharmaceuticals PLC FRA:J7Z
74 GF Score
Price €209.50
GF Value €130.22
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Current Deferred Revenue?

Jazz Pharmaceuticals FRA:J7Z -3.01% 74 Current Deferred Revenue is €0 Mil as of Jun. 2026. GuruFocus rates FRA:J7Z with a GF Score™ of 74/100 and a GF Value™ of €130.22 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Jazz Pharmaceuticals's current deferred revenue for the quarter that ended in Jun. 2026 was €0 Mil.

Jazz Pharmaceuticals Current Deferred Revenue Related Terms

Jazz Pharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Current Deferred Revenue Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.85 0.44 0.00 0.00 0.00

Jazz Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:J7Z
74GF Score
Jazz Pharmaceuticals PLC FRA:J7Z
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0 Mil mean?
Jazz Pharmaceuticals (FRA:J7Z) has a Current Deferred Revenue of €0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Current Deferred Revenue too high?
Jazz Pharmaceuticals' current Current Deferred Revenue is €0 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Current Deferred Revenue compare to ASND and BBIO?
Jazz Pharmaceuticals' Current Deferred Revenue of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Current Deferred Revenue is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €130.22, compared to a current price of €209.50 — trading 60.9% above its estimated fair value. The current Current Deferred Revenue is €0 Mil. Jazz Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current Current Deferred Revenue is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of €209.50 is trading 60.9% above its estimated GF Value™ of €130.22. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:J7Z:

  • Current Deferred Revenue: €0 Mil
  • GF Value™: €130.22 vs. price of €209.50 (60.9% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
74GF Score

Get the complete analysis for FRA:J7Z

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€209.50
Price
€130.22
GF Value